๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Recurrent Glioblastoma
Clinical trial register · China

Recurrent Glioblastoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Shanghai 2 Shenzhen 2 Zhuhai 1 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Shanghai2 Shenzhen2 Zhuhai1 Hangzhou1
All 9 locations
Target enrolment
to

Recurrent Glioblastoma trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
NCT07648823Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
Beijing Tiantan Hospital
Phase EARLY_PHASE1
5
Beijing
2026-06-20
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07480941Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
Beijing Biotech
Phase 1
36
Shenzhen
2026-02-02
Recruiting
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT07297212Recurrent Glioblastoma
BioNTech SE
Phase 2
75
Beijing, Chongqing, Jinan, Shanghai, Shenzhen, Wuhan
2026-01-15
Recruiting
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
NCT07193628Refractory Glioblastoma, Recurrent Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
14
Hangzhou
2025-09-26
Recruiting
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
NCT07538128Recurrent Glioblastoma
Huashan Hospital
Phase EARLY_PHASE1
10
Shanghai
2025-01-09
Recruiting
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
NCT06598787Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-10-17
Recruiting
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
NCT06220552Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
20
Zhuhai
2023-12-27
Not yet open
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
NCT05540275Recurrent Glioblastoma
Henan Provincial People's Hospital
Phase 2
30
Zhengzhou
2023-10-05
Recruiting
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
NCT05577091Recurrent Glioblastoma
Beijing Tiantan Hospital
Phase 1
10
Beijing
2023-09-30
Active, closed
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
NCT05118776Recurrent Glioblastoma
Ascletis Pharmaceuticals Co., Ltd.
Phase 3
136
Beijing
2022-01-21
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/recurrent-glioblastoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Recurrent Glioblastoma.

How many Recurrent Glioblastoma trials are recruiting in China?

8 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Recurrent Glioblastoma), 10 studies
PhaseStudiesRecruitingShare
Phase 24340%
Phase 13330%
Phase EARLY_PHASE12220%
Phase 31010%

Most active sponsors

Lead sponsors with the most studies (Recurrent Glioblastoma)
Lead sponsorStudiesRecruiting
Beijing Tiantan Hospital22
Ascletis Pharmaceuticals Co., Ltd.10
Beijing Biotech11
BioNTech SE11
Fifth Affiliated Hospital, Sun Yat-Sen University11
Henan Provincial People's Hospital10
Huashan Hospital11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Sichuan Baili Pharmaceutical Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.